Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 3/20 | 0.55 |
| ▸ | BCHE | P06276 | 2/20 | 0.55 |
| ▸ | MAOA | P21397 | 3/20 | 0.53 |
| ▸ | MAOB | P27338 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | STAT6 | P42226 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 6/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.47 |
| ▸ | HTT | P42858 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29445058 | 1.00 | ACHE (0.55) | ACHEBCHEMAOAMAOBTP53 | |
| SCHEMBL24277044 | 0.91 | ACHE (0.57) | ACHEBCHEMAOAMAOBTP53 | |
| SCHEMBL24277252 | 0.82 | HPGD (0.47) | ACHEBCHEMAOAMAOBTP53 | |
| SCHEMBL24277244 | 0.82 | TOP2A (0.48) | ACHEBCHEMAPTTOP2AKIT | |
| SCHEMBL29445106 | 0.82 | TOP2A (0.48) | ACHEBCHEMAPTTOP2AKIT | |
| SCHEMBL24277130 | 0.81 | MAPT (0.55) | ACHEBCHEMAOAMAOBTP53 | |
| SCHEMBL29445173 | 0.81 | DYRK1A (0.57) | ACHEBCHEMAOAMAOBTP53 | |
| SCHEMBL11835361 | 0.81 | CYP1A2 (0.69) | ACHEBCHEMAOAMAOBTP53 | |
| SCHEMBL24277272 | 0.81 | DYRK1A (0.57) | ACHEBCHEMAOAMAOBTP53 | |
| SCHEMBL24277100 | 0.81 | TOP2A (0.41) | ACHEBCHEMAOAMAOBTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067639-A1 | SMALL MOLECULES THAT TARGET THE RNA THAT CAUSES ALS | University of Florida Research Foundation, Incorporation (US) | 2024-02-29 | — | — | US | disclosed |
| US-20240067639-A1 | SMALL MOLECULES THAT TARGET THE RNA THAT CAUSES ALS | University of Florida Research Foundation, Incorporation (US) | 2024-02-29 | — | — | US | disclosed |
| US-20240067639-A1 | SMALL MOLECULES THAT TARGET THE RNA THAT CAUSES ALS | University of Florida Research Foundation, Incorporation (US) | 2024-02-29 | — | — | US | disclosed |
| EP-4210703-A1 | SMALL MOLECULES THAT TARGET THE RNA THAT CAUSES ALS | Expansion Therapeutics, Inc. (US) | 2023-07-19 | — | — | EP | disclosed |
| WO-2022055922-A1 | SMALL MOLECULES THAT TARGET THE RNA THAT CAUSES ALS | EXPANSION THERAPEUTICS, INC. (US) | 2022-03-17 | — | — | WO | disclosed |
| WO-2022055922-A1 | SMALL MOLECULES THAT TARGET THE RNA THAT CAUSES ALS | EXPANSION THERAPEUTICS, INC. (US) | 2022-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240067639-A1 | SMALL MOLECULES THAT TARGET THE RNA THAT CAUSES ALS | FUS, SNRPE, RRBP1 | ACHE 3631/4885BCHE 3340/4885MAOA 4540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.